Results 21 to 30 of about 29,420 (294)

Evaluation of a Novel FKS1 R1354H Mutation Associated with Caspofungin Resistance in Candida auris Using the CRISPR-Cas9 System

Journal of Fungi, 2023
Outbreaks of invasive infections, with high mortality rates, caused by multidrug-resistant Candida auris have been reported worldwide. Although hotspot mutations in FKS1 are an established cause of echinocandin resistance, the actual contribution of ...
Maiko Kiyohara, T. Miyazaki, Michiyo Okamoto, T. Hirayama, K. Makimura, H. Chibana, Nana Nakada, Y. Ito, Makoto Sumiyoshi, N. Ashizawa, K. Takeda, N. Iwanaga, T. Takazono, K. Izumikawa, K. Yanagihara, S. Kohno, H. Mukae   +16 more
semanticscholar   +1 more source

A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi

bioRxiv, 2022
Current treatment of fungal infections is threatened by emerging antifungal drug resistance. In this work, the authors explore the synergistic activity of a host defense peptide mimetic, brilacidin, with caspofungin against a panel of fungal strains ...
Thaila Fernanda dos Reis, Patrícia Alves de Castro, R. W. Bastos, C. Pinzan, P. F. Souza, S. Ackloo, M. A. Hossain, D. Drewry, Sondus Alkhazraji, A. Ibrahim, Hyunil Jo, W. DeGrado, G. Goldman   +12 more
semanticscholar   +1 more source

Caspofungin Affects Extracellular Vesicle Production and Cargo in Candida auris

Journal of Fungi, 2022
Antifungal resistance has become more frequent, either due to the emergence of naturally resistant species or the development of mechanisms that lead to resistance in previously susceptible species.
R. Amatuzzi, Daniel Zamith-Miranda, I. F. Munhoz da Rocha, A. C. Lucena, Sharon de Toledo Martins, R. Streit, C. Staats, Gabriel Trentin, Fausto Almeida, M. Rodrigues, J. Nosanchuk, Lysangela R Alves   +11 more
semanticscholar   +1 more source

Puf4 Mediates Post-transcriptional Regulation of Cell Wall Biosynthesis and Caspofungin Resistance in Cryptococcus neoformans

mBio, 2021
Cryptococcus neoformans is an environmental fungus that causes pulmonary and central nervous system infections. It is also responsible for 15% of AIDS-related deaths.
Murat C. Kalem, H. Subbiah, Jay Leipheimer, Virginia E Glazier, J. Panepinto   +4 more
semanticscholar   +1 more source

In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms

bioRxiv, 2021
The in vitro and in vivo efficacy of caspofungin was determined in combination with isavuconazole against Candida auris. Drug–drug interactions were assessed utilising the fractional inhibitory concentration indices (FICIs), the Bliss independence model ...
F. Nagy, Zoltán Tóth, Fanni Nyikos, Lajos Forgács, Á. Jakab, A. Borman, L. Majoros, R. Kovács   +7 more
semanticscholar   +1 more source

Heterogeneity in the transcriptional response of the human pathogen Aspergillus fumigatus to the antifungal agent caspofungin

bioRxiv, 2021
Aspergillus fumigatus is the main causative agent of invasive pulmonary aspergillosis (IPA), a severe disease that affects immunosuppressed patients worldwide.
A. C. Colabardini, Fang Wang, Zhiqiang Dong, Lakhansing Pardeshi, M. C. Rocha, J. H. Costa, T. F. dos Reis, Alec Brown, Qais Z. Jaber, M. Fridman, T. Fill, A. Rokas, I. Malavazi, K. H. Wong, G. Goldman   +14 more
semanticscholar   +1 more source

Pharmacokinetics of caspofungin in ICU patients [PDF]

Journal of Antimicrobial Chemotherapy, 2014
Caspofungin is used for treatment of invasive fungal infections. As the pharmacokinetics (PK) of antimicrobial agents in critically ill patients can be highly variable, we set out to explore caspofungin PK in ICU patients.ICU patients receiving caspofungin were eligible.
Muilwijk, E.W., Schouten, J.A., Leeuwen, H.J. van, Zanten, A.R. van, Lange, D.W. de, Colbers, A., Verweij, P.E., Burger, D.M., Pickkers, P., Bruggemann, R.J.M.   +9 more
openaire   +4 more sources

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial

Clinical Infectious Diseases, 2020
Background Rezafungin (RZF) is a novel echinocandin exhibiting distinctive pharmacokinetics/pharmacodynamics. STRIVE was a phase 2, double-blind, randomized trial designed to compare the safety and efficacy of RZF once weekly (QWk) to caspofungin (CAS ...
G. Thompson, Á. Soriano, A. Skoutelis, J. Vázquez, P. Honore, J. Horcajada, H. Spapen, M. Bassetti, L. Ostrosky-Zeichner, Anita F. Das, R. Viani, T. Sandison, P. Pappas   +12 more
semanticscholar   +1 more source

In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris

Pharmaceutics, 2021
Treatment of invasive infections caused by Candida auris is challenging due to the limited therapeutic options. The combination of antifungal drugs may be an interesting and feasible approach to be investigated.
Unai Caballero, E. Eraso, G. Quindós, N. Jauregizar   +3 more
semanticscholar   +1 more source

Cellular apoptosis: An alternative mechanism of action for caspofungin against Candida glabrata [PDF]

Current Medical Mycology, 2019
Background and Purpose: Although the mechanism of action for echinocandins is known, the physiological mechanisms by which these antifungal agents cause cell death via the classical apoptotic pathways are not well-defined yet. Regarding this, the present
Parisa Aryamloo, Hossein Asgarian-Omran, Narges Aslani, Hadi Hossein-Nataj, Tahereh Shokohi, Hamid Badali, Mojtaba Nabili, Atefeh Abdollahi Gohar, Maryam Moazeni   +8 more
doaj   +1 more source